11/18
07:45 am
oprx
OptimizeRx to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
OptimizeRx to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/18
07:30 am
oprx
OptimizeRx to Participate in Upcoming Investor Conferences
Medium
Report
OptimizeRx to Participate in Upcoming Investor Conferences
11/14
06:29 pm
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
OptimizeRx Co. (NASDAQ: OPRX) had its "outperform" rating re-affirmed by analysts at William Blair.
11/14
12:07 pm
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Royal Bank of Canada from $14.00 to $7.00. They now have an "outperform" rating on the stock.
Low
Report
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Royal Bank of Canada from $14.00 to $7.00. They now have an "outperform" rating on the stock.
11/14
11:13 am
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $16.00 price target on the stock, down previously from $20.00.
Low
Report
OptimizeRx Co. (NASDAQ: OPRX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $16.00 price target on the stock, down previously from $20.00.
11/14
10:12 am
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Stifel Nicolaus from $13.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Stifel Nicolaus from $13.00 to $8.00. They now have a "buy" rating on the stock.
11/14
09:06 am
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Barclays PLC from $11.00 to $5.00. They now have an "equal weight" rating on the stock.
High
Report
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at Barclays PLC from $11.00 to $5.00. They now have an "equal weight" rating on the stock.
11/14
08:15 am
oprx
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at JMP Securities from $16.00 to $8.00. They now have a "market outperform" rating on the stock.
High
Report
OptimizeRx Co. (NASDAQ: OPRX) had its price target lowered by analysts at JMP Securities from $16.00 to $8.00. They now have a "market outperform" rating on the stock.
11/14
02:31 am
oprx
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... [Yahoo! Finance]
High
Report
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... [Yahoo! Finance]
11/13
11:01 pm
oprx
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
High
Report
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/13
04:05 pm
oprx
OptimizeRx Reports Third Quarter 2024 Financial Results
High
Report
OptimizeRx Reports Third Quarter 2024 Financial Results
11/7
10:32 am
oprx
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains? [Yahoo! Finance]
10/31
07:30 am
oprx
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
Medium
Report
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
10/3
05:56 am
oprx
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last? [Yahoo! Finance]
9/10
07:30 am
oprx
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
Low
Report
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
9/9
12:00 pm
oprx
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
Medium
Report
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences